A- A A+

Medications for opioid use disorders: clinical and pharmacological considerations. 

Volkow ND, Blanco C. 

J Clin Invest. 2020;130(1):10-13. doi:10.1172/JCI134708

Medications for opioid use disorders: clinical and pharmacological considerations. 

Precision therapeutic opioid dosing implications from genetic biomarkers and craving score.

Chang HW, Ho WC, Huang CL, Wang RY. 

Medicine (Baltimore). 2020;99(22):e20429. doi:10.1097/MD.0000000000020429

https://journals.lww.com/md-journal/FullText/2020/05290/Precision_therapeutic_opioid_dosing_implications.89.aspx

Consequences of Opioid Abuse and their Treatments in Persian Medicine: A Review Study. 

Kamali M, Tajadini H, Mehrabani M, Moghadari M. 

Addict Health. 2020;12(1):46-57. doi:10.22122/ahj.v12i1.250

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291898/

Effects of Medication-Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes: A Systematic Review. 

Maglione MA, Laura R, Christine C, et al. 

Rand Health Q. 2020;8(4):RR-2108-OSD. Published 2020 Jun 15. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302321/

 

Tackling the overdose crisis: The role of safe supply 

Ivsins A, Boyd J, Beletsky L, McNeil R. 

[published online ahead of print, 2020 May 1]. Int J Drug Policy. 2020;80:102769. doi:10.1016/j.drugpo.2020.102769

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252037/

Retention of patients in opioid substitution treatment: A systematic review.

O’Connor AM, Cousins G, Durand L, Barry J, Boland F (2020) 

PLoS ONE 15(5): e0232086. doi.org/10.1371/journal.pone.0232086

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0232086

Opioid agonist treatment reduces losses in quality of life and quality-adjusted life expectancy in heroin users: Evidence from real world data.

Chang KC, Lee KY, Lu TH, Hwang JS, Lin CN, Ting SY, Chang CC, Wang JD.

Drug Alcohol Depend. 2019 Aug 1;201:197-204. doi: 10.1016/j.drugalcdep.2019.05.003. 

https://www.sciencedirect.com/science/article/pii/S0376871619301863?via%3Dihub

Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment.

Yedinak JL, Goedel WC, Paull K, Lebeau R, Krieger MS, Thompson C, et al. (2019) 

PLoS Med 16(11): e1002963. doi.org/10.1371/journal.pmed.1002963

https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002963

Opioid and Polydrug Use Among Patients in Opioid Maintenance Treatment.

Carlsen SL, Lunde LH, Torsheim T.

Subst Abuse Rehabil. 2020 Jan 29;11:9-18. doi: 10.2147/SAR.S221618. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996215/

Hab-o Shefa, a Persian Medicine Compound for Maintenance Treatment of Opioid Dependence: Randomized Placebo-Controlled Clinical Trial.

Moosavyzadeh A, Mokri A, Ghaffari F, Faghihzadeh S, Azizi H, Jafari Hajati R, Naseri M.

J Altern Complement Med. 2020 Feb 28. doi: 10.1089/acm.2019.0390. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/32109133

Opioid use disorder and treatment: challenges and opportunities.

Hoffman KA, Ponce Terashima J, McCarty D.

BMC Health Serv Res. 2019 Nov 25;19(1):884. doi: 10.1186/s12913-019-4751-4. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876068/

Adjunctive memantine for opioid use disorder treatment: A systematic review.

Elias AM, Pepin MJ, Brown JN.

J Subst Abuse Treat. 2019 Dec;107:38-43. doi: 10.1016/j.jsat.2019.10.003.

https://www.ncbi.nlm.nih.gov/pubmed/31757263

Fentanyl assisted treatment: a possible role in the opioid overdose epidemic?

Bardwell G, Wood E, Brar R.

Subst Abuse Treat Prev Policy. 2019 Nov 11;14(1):50. doi: 10.1186/s13011-019-0241-2.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849248/

Sustained-release Oral Hydromorphone for the Treatment of Opioid Use Disorder.

Braithwaite V, Fairgrieve C, Nolan S.

J Addict Med. 2019 Oct 25. doi: 10.1097/ADM.0000000000000585. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31658114

Neue Substitutionsprodukte, neue Chancen? Der Wurm muss dem Fisch schmecken, nicht dem Angler (Präsentation)

Dr. Manfred Nowak, Landau

NaSuKo – 5.Nationale Substitutionskonferenz, 27.09.2019, Berlin

https://www.akzept.eu/wp-content/uploads/2019/10/NeueSubstitutionsmittelNowak.pdf

Current status of opioid addiction treatment and related preclinical research.

Kreek MJ, Reed B, Butelman ER.

Sci Adv. 2019 Oct 2;5(10):eaax9140. doi: 10.1126/sciadv.aax9140. eCollection 2019 Oct. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774730/

Norwegen. 'The entire pharmaceutical compendium' in the treatment of substance use disorders

Jørg Mørland, Helge Waal

Tidsskr Nor Legeforen 2019, doi: 10.4045/tidsskr.18.0678

https://tidsskriftet.no/en/2019/02/kronikk/entire-pharmaceutical-compendium-treatment-substance-use-disorders

Medication-Assisted Treatment for Opioid-Use Disorder.

Tyler S. Oesterle, Nuria J. Thusius, Teresa A. Rummans, Mark S. Gold. 

Mayo Clinic Proceedings, 2019; DOI: 10.1016/j.mayocp.2019.03.029

https://www.mayoclinicproceedings.org/article/S0025-6196(19)30393-3/fulltext

Anästhesievorbereitung: Welche Medikamente vor einer Narkose abgesetzt werden sollten

Schreiner, Mathias J.; Kehl, Franz

Dtsch Arztebl 2019; 116(31-32): A-1428 / B-1183 / C-1167

https://www.aerzteblatt.de/archiv/209139/Anaesthesievorbereitung-Welche-Medikamente-vor-einer-Narkose-abgesetzt-werden-sollten

Pain management in opioid maintenance treatment.

Koller G, Schwarzer A, Halfter K, Soyka M.

Expert Opin Pharmacother. 2019 Aug 16:1-13. doi: 10.1080/14656566.2019.1652270. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31418602

Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review.

Wang SC, Chen YC, Lee CH, Cheng CM.

Int J Mol Sci. 2019 Sep 2;20(17). pii: E4294. doi: 10.3390/ijms20174294.

https://www.mdpi.com/1422-0067/20/17/4294/htm

Effects of Parental Opioid Use: Outcomes of Children of Parents in Medication-Assisted Treatment Compared to Healthy Controls.

Betcher HK, Vande Voort JL, Croarkin PE, Gandhi KD, Shekunov J, Larrabee BR, Limbeck MG, Rummans TA, Romanowicz M.

Prim Care Companion CNS Disord. 2019 Aug 15;21(4). pii: 19m02474. doi: 10.4088/PCC.19m02474.

http://www.psychiatrist.com/pcc/article/pages/2019/v21n04/19m02474.aspx

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY.

Ann Intern Med. 2018 Aug 7;169(3):137-145. doi: 10.7326/M17-3107. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387681/

Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.

Molero Y, Zetterqvist J, Binswanger IA, Hellner C, Larsson H, Fazel S.

Am J Psychiatry. 2018 Oct 1;175(10):970-978. doi: 10.1176/appi.ajp.2018.17101112. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169735/

Opioid Use Disorders: Perioperative Management of a Special Population.

Ward EN, Quaye AN, Wilens TE.

Anesth Analg. 2018 Aug;127(2):539-547. doi: 10.1213/ANE.0000000000003477. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523021/

Palliativversorgung von Patienten in Opioidsubstitutionsbehandlung (mit CME)

Hoffmann-Menzel, J.Goldmann, M.Kern, K.Weckbecker, L. Wüllenweber, L. Radbruch

Schmerz 2019 · 33:263–280, doi.org/10.1007/s00482-019-0376-0

Abstract (freier Zugang für 14 Tage möglich)

Korrespondenzadresse: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!

https://www.springermedizin.de/palliative-schmerztherapie/sucht/palliativversorgung-von-patienten-in-opioidsubstitutionsbehandlu/16728648

Sex differences in high opioid dose escalation among Malaysian patients with long term opioid therapy.

Zin CS, Alias NE, Taufek NH, Ahmad MM.

J Pain Res. 2019 Apr 24;12:1251-1257. doi: 10.2147/JPR.S199243.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499483/

Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood.

Leventelis C, Goutzourelas N, Kortsinidou A, Spanidis Y, Toulia G, Kampitsi A, Tsitsimpikou C, Stagos D, Veskoukis AS, Kouretas D.

Oxid Med Cell Longev. 2019 Apr 9;2019:9417048. doi: 10.1155/2019/9417048.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481042/

Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.

Gastberger S, Baumgartner MR, Soyka M, Quednow BB, Hulka LM, Herdener M, Seifritz E, Mutschler J.

Eur Addict Res. 2019 May 8:1-6. doi: 10.1159/000500542. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31067528

Detection of heroin intake in patients in substitution treatment using oral fluid as specimen for drug testing.

Böttcher M, Lierheimer S, Peschel A, Beck O.

Drug Alcohol Depend. 2019 Mar 23;198:136-139. doi: 10.1016/j.drugalcdep.2019.02.011.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30927716

  1. Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review.
  2. Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.
  3. Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.
  4. Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?.
  5. Temperamental Characteristics and Problem-Solving Skills among Patients on Opioid Agonists.